Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Inclisiran offers substantial LDL-C reductions in ASCVD patients Next Article
Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin »
« Inclisiran offers substantial LDL-C reductions in ASCVD patients Next Article
Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin »
Related Articles
June 1, 2022
First results of the POWER FAST III trial
February 15, 2022
Multiple sleep problems may boost heart disease risk by more than 140%
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy